MAQS has advised IRLAB Therapeutics AB in connection with admission to trading of the Company’s shares of series A on Nasdaq Stockholm Main Market

IRLAB Therapeutics AB (”IRLAB”) is a Swedish pharmaceutical research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have completed Phase IIa-studies, intend to treat some of the most difficult symptoms related to Parkinson's disease.

IRLAB’s shares of series A have been listed on Nasdaq First North Premier Growth Market since February 2017.

The first day of trading on Nasdaq Stockholm Main Market was today, Wednesday, 30 September 2020.

MAQS’ team consisted of Dag Fredlund, Hanna Friberg, Jonas Svahn, Daniel Thorbjörnsson, Eric Ehrencrona and Niklas Eskilsson.